Imeglimin → Chemotherapy-Induced Cognitive Impairment

Original Indication

Antidiabetic medication (Type 2 Diabetes)

Proposed New Indication

Imeglimin shows potential for treating Chemotherapy-Induced Cognitive Impairment (CICI) by targeting mitochondrial dysfunction and neuroinflammation, a severe side effect of cancer treatment.

Proposed Mechanism

Targets: Mitochondrial_Bioenergetics, NF-kB, TNF-alpha, IL-6, Insulin_Sensitivity

Imeglimin enhances mitochondrial O2 uptake, increases membrane potentials, diminishes oxidative stress, and acts as an antioxidant. It also suppresses NF-κB signaling and reduces pro-inflammatory cytokines TNF-α and IL-6. Additionally, it improves insulin sensitivity and modulates brain glucose metabolism.

Evidence

Level: Review/Hypothesis (Preclinical and clinical evaluation warranted)

Source: Kondaveeti, S. B., et al. (2026). Repurposing Imeglimin for Chemotherapy-Induced Cognitive Impairment: Targeting Mitochondrial Dysfunction and Neuroinflammation. Cell Mol Neurobiol.

Reference: PubMed 41665826

Repurposing Score